Food and Behaviour Research

Donate Log In

UK Nutrient Gaps and Impacts on Early Development with Dr Emma Derbyshire and TC Callis - BOOK HERE

Meta-analysis supports potential of omega-3s for ADHD

Stephen Daniells

omega-3 improves symptoms of ADHD

Omega-3 supplements can reduce ADHD symptoms - Meta-analysis of clinical trials

FAB RESEARCH COMMENT:

In this new systematic review, conducted to the most rigorous standards for scientific reporting, researchers used meta-analyses to pool the results from two kinds of studies investigating omega-3 long-chain polyunsaturated fatty acids (LC-PUFA) in relation to Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents:

(1) Randomised controlled clinical trials (RCT) investigating the effects of supplementation with omega-3 LC-PUFA (EPA and/or DHA) in children or adolescents with ADHD, and

(2) Biochemical studies assessing the blood or tissue omega-3 LC-PUFA status of ADHD children or adolescents vs matched controls

  • Findings from biochemical studies confirmed previous reports that individuals with ADHD show significantly lower omega-3 LC-PUFA status than matched controls. 
The reasons for this still require further investigation, although previous studies have provided some evidence that metabolic differences - rather than, or in addition to, low dietary intakes - may help to account for the low omega-3 status repeatedly found in association with ADHD.

  • Results from clinical trials showed that omega-3 supplementation reduced ADHD symptoms of both inattention and hyperactivity as rated by parents (but not teachers) - although benefits for hyperactivity were only seen when the supplementation provided at least 500mg/day of EPA.

As the researchers note, these findings provide further support to the rationale for using omega-3 LC-PUFA as a treatment option for ADHD - particularly for individuals for whom medications may not be appropriate.


For details of this research, see:

See also:


And for more news and research articles on the subject of ADHD and omega-3 polyunsaturated fatty acids, please see the following lists, which are regularly updated:

31 July 2017 - Nutraingredients

-----------------------------------

Omega-3s fatty acid supplements may improve symptoms and cognitive performance in children and adolescents with attention deficit hyperactivity disorder (ADHD), according to a meta-analysis of gold standard clinical trials.

Data from seven clinical trials involving over 500 children and adolescents indicated that omega-3s were associated with improvements in clinical symptoms of ADHD, while data from three clinical trials involving over 200 children and adolescents indicated a positive impact on cognitive measures associated with attention.

“[W]e provide strong evidence supporting a role for n3-PUFAs deficiency in ADHD, and for advocating n-3 PUFAs supplementation as a clinically relevant intervention in this group, especially if guided by a biomarker-based personalization approach,” wrote the authors, led by Jane Pei-Chen Chang from King’s College London, in Neuropsychopharmacology.

Boosting EPA/DHA intakes

Commenting independently on the meta-analysis, Harry Rice, PhD, VP of regulatory & scientific affairs for the Global Organization for EPA and DHA Omega-3s (GOED): “In the past, I've been lukewarm on whether or not increasing EPA/DHA intake benefits children with ADHD. Results from this meta-analysis put me a little closer to believing.

“Minimally, given the low side effect profile of omega-3s versus the drugs of choice to treat ADHD, I would highly recommend first increasing intake of EPA/DHA. This is particularly true if a child doesn't eat at least two servings of fatty fish a week or doesn't take an omega-3 supplement on a regular basis.”

Meta-analysis details

The new meta-analysis was performed using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines and used established scientific literature databases to identify appropriate studies for inclusion.

Data from seven randomized controlled trials (RCTs) with 534 young people indicated that that omega-s3 supplementation significantly improved inattention and hyperactivity symptoms, according to parental reports.

Additional analysis revealed that the improvements in hyperactivity were only observed when doses of EPA (eicosapentaenoic acid) of 500 mg/day or more were used.

Interestingly, the researchers did not find improvements in hyperactivity and inattention when they looked at teacher’s reports, unlike what was reported by parents.

Omega-3 supplements were associated with improvements in select measures of cognitive performance, said the researchers.

“N-3 PUFAs are crucial for optimal neurotransmitter function: for example, incorporating more EPA and DHA in the cell membrane can increase cholesterol efflux, modulate lipid raft clustering and disruption, and affect the function of the dopamine transporter (DAT), which in turn may affect attention and executive function by regulating synaptic dopamine levels,” wrote the researchers.

Omega-3 levels

Data from case-control studies were also collected to assess if omega-3 levels were also associated with ADHD, with results indicating that children and adolescents with ADHD had lower levels of EPA, DHA (docosahexaenoic acid),and total omega-3s.

“In the context of ‘personalised medicine’, it is tempting to speculate that a subpopulation of youth with ADHD and with low levels of n-3 PUFAs may respond better to n-3 PUFAs supplementation, but there are no studies to date attempting this stratification approach,” wrote the researchers.

“However, we have [previously] shown that individuals at genetic risk of developing depression in the context of the immune challenge, interferon-alpha (IFN-alpha), have lower levels of RBCs n3-PUFAs, and that n-3 PUFAs supplementation prevents the onset of IFN-alpha-induced depression, arguably by replenishing the endogenously low anti-inflammatory PUFAs in the ‘at risk’ individuals.”

“Moreover, a recent study by Rapaport [Mol Psychiatry, 2016, Vol. 21, pp. 71–79] has stratified patients with major depressive disorder into a ‘high’ and a ‘low’ inflammation group, and shown that the ‘high inflammation’ group has a better responses to EPA [...] Therefore, stratification of ADHD children by n-3 PUFAs levels or by immune biomarkers could be one approach to optimise the therapeutic effects of n-3 PUFAs supplementation.”